1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Decibel Therapeutics: Protect. Repair. Restore.

 
• By Lubna Ahmed

Emerging Company Profile: Decibel Therapeutics, a Boston-based company focused on developing therapies for hearing loss, started adding its voice in an emerging development space in 2015, with the aim of becoming "the premier hearing therapies company." With ongoing research and preclinical candidates for hearing loss, Decibel is looking to secure a beneficial collaboration that will bump up its profile and give it the funding it needs to move forward.

There are no therapies currently available for hearing loss that protect or restore hearing, Decibel Therapeutics' CEO Steven Holtzman told Scrip, describing the area as a "white space." The condition is currently managed using medical devices like hearing aids and cochlear implants, but Decibel aims to change the standard of care by developing effective pharmaceuticals to help protect, repair and restore hearing.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.